Cs-1008 (Not yet branded)
Other Medications
Description
CS-1008 is a humanized monoclonal antibody that targets the death receptor 5 (DR5) pathway for apoptosis induction in cancer cells. Based on clinical trial data, it has been evaluated specifically in metastatic colorectal cancer patients who have failed first-line oxaliplatin-based treatment. The drug was tested both as monotherapy and in combination with irinotecan-containing regimens like FOLFIRI in patients with advanced disease.
Mechanism of Action
CS-1008 binds to death receptor 5 (DR5), also known as TRAIL-R2, which is expressed on the surface of many cancer cells. Upon binding, it activates the extrinsic apoptotic pathway by triggering caspase cascades that lead to programmed cell death in malignant cells while sparing normal tissues that are less sensitive to this death receptor signaling.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.